These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 19660877)

  • 1. Revisiting the possibility of serious adverse events from the whole cell pertussis vaccine: were metabolically vulnerable children at risk?
    Wilson K; Potter B; Manuel D; Keelan J; Chakraborty P
    Med Hypotheses; 2010 Jan; 74(1):150-4. PubMed ID: 19660877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactogenicity of infant whole cell pertussis combination vaccine compared with acellular pertussis vaccines with or without simultaneous pneumococcal vaccine in the Netherlands.
    David S; Vermeer-de Bondt PE; van der Maas NA
    Vaccine; 2008 Oct; 26(46):5883-7. PubMed ID: 18775463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of adverse effects following immunization with vaccine containing whole-cell vs. acellular pertussis components.
    Zieliński A; Rosińska M
    Przegl Epidemiol; 2008; 62(3):589-96. PubMed ID: 19108523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits and risks of immunization against pertussis.
    Stuart-Harris C
    Dev Biol Stand; 1979; 43():75-83. PubMed ID: 520687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pertussis: a reemerging infection?].
    Kriz B; Fabiánová K; Maixnerová M; Benes C; Malý M
    Epidemiol Mikrobiol Imunol; 2007 Apr; 56(2):51-65. PubMed ID: 17593802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of serious neurological disorders following immunization: a comparison of whole-cell pertussis and acellular pertussis vaccines.
    Geier DA; Geier MR
    Brain Dev; 2004 Aug; 26(5):296-300. PubMed ID: 15165669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prevention of pertussis and high expectations concerning vaccines].
    Wysocki J
    Przegl Epidemiol; 2004; 58 Suppl 1():39-43. PubMed ID: 15807156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Safety surveillance in the National Vaccination Programme; fewer adverse events with the DTP-IPV-Hib vaccine after the transition to an acellular pertussis component in 2005].
    van der Maas NA; David S; Kemmeren JM; Vermeer-de Bondt PE
    Ned Tijdschr Geneeskd; 2007 Dec; 151(49):2732-7. PubMed ID: 18225797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on vaccine safety.
    Zimmerman RK; Kimmel SR; Trauth JM
    Am Fam Physician; 1996 Jul; 54(1):185-93. PubMed ID: 8677834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical studies on efficacy and safety of an acellular pertussis vaccine in Aichi Prefecture, Japan.
    Isomura S
    Dev Biol Stand; 1991; 73():37-42. PubMed ID: 1778331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age at pertussis immunization as it relates to current epidemiology and disease control.
    Funkhouser AW; Wassilak SG; Hinman AR; Orenstein WA; Mortimer EA
    Tokai J Exp Clin Med; 1988; 13 Suppl():111-5. PubMed ID: 3273610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pertussis vaccine controversy.
    Hinman AR
    Public Health Rep; 1984; 99(3):255-9. PubMed ID: 6429722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pertussis in adolescents and adults: should we vaccinate?
    Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
    Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse events following immunization with DTP vaccine.
    Stetler HC; Mullen JR; Brennan JP; Orenstein WA; Bart KJ; Hinman AR
    Dev Biol Stand; 1985; 61():411-21. PubMed ID: 3879686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acellular pertussis vaccination of 2-month-old infants in the United States.
    Pichichero ME; Francis AB; Blatter MM; Reisinger KS; Green JL; Marsocci SM; Disney FA
    Pediatrics; 1992 May; 89(5 Pt 1):882-7. PubMed ID: 1579399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tolerance of acellular pertussis vaccine booster injection in 15-20-month-old children].
    Mallet E; Puyt A; Arson S; Surbled V
    Arch Pediatr; 2000 Apr; 7(4):410-4. PubMed ID: 10793931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sequelae of vaccination following preventive pertussis vaccination in West Germany (1970 to 1978)].
    Ehrengut W
    Offentl Gesundheitswes; 1986 Mar; 48(3):123-6. PubMed ID: 2940489
    [No Abstract]   [Full Text] [Related]  

  • 19. Results with a new DTP vaccine in Japan.
    Kimura M; Hikino N
    Dev Biol Stand; 1985; 61():545-61. PubMed ID: 2872131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control of pertussis in the world.
    Galazka A
    World Health Stat Q; 1992; 45(2-3):238-47. PubMed ID: 1462658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.